Skip to content

IGM Biosciences

  • About Us
    • Our Company
    • Leadership Team
  • IGM Platform
    • Our IGM Platform
    • Publications
    • Presentations
  • Pipeline & Programs
    • Pipeline
    • Imvotamab
    • IGM-8444
    • IGM-7354
    • IGM-2644
  • Investors & News
  • Join Us
    • Our Culture
    • Open Jobs
  • Contact Us
Presentations
  • 2022
  • 2021
  • 2020
  • 2019
December 2019

High Avidity IgM-based CD20xCD3 Bispecific Antibody for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

American Society of Hematology (ASH) Annual Meeting – December 7-10, 2019

Read more
November 2019

Agonist and Bispecific IgM: Nature’s Approach to Highly Avid, Multivalent Antibodies

PEGS Europe – November, 2019

Read more

All content © IGM Biosciences, Inc.    info@igmbio.com    Site Credits

LinkedIn